Acute Coronary Syndromes

Ischemia Modified Albumin test to be reimbursed by Medicare

Published in Biotech Business Week, December 20th, 2004

Ischemia Technologies, Inc., announced that its in vitro diagnostic test for cardiac ischemia, Ischemia Modified Albumin (IMA), will be reimbursed by Medicare beginning January 1, 2005, at $47.43 per test.

This amount is the national fee limit (state and local rates may vary slightly), and exceeds the average cost per test paid by laboratories.

A new Common Procedural Terminology code for IMA (82045: albumin, ischemia modified) has also been established, and will be used beginning January 1, 2005, to report and bill for IMA testing.

"Inclusion in the 2005 Medicare lab fee schedule makes it much easier for hospitals to order and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry